Current Chemotherapy Use in Neuroendocrine Tumors.
The role of chemotherapy in neuroendocrine tumors (NETs) has evolved with the development of other effective systemic therapies. At the same time, the evolving classification of NETs by grade has allowed for prognostic stratification. Chemotherapy is not routinely used for grade 1 to 2 NETs, but capecitabine (CAPTEM) or streptozocin-based regimens may be used, particularly for pancreatic NETs. In contrast, poorly differentiated grade 3 NETs are usually treated with platinum doublet chemotherapy. There is no consensus for the treatment of well-differentiated G3 NETs, but platinum doublets or CAPTEM are reasonable options.